Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | TTK | P33981 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL27458465 | 0.80 | NOTUM (0.44) | MAPTTHRBAURKACASP1TTK | |
| SCHEMBL10888011 | 0.79 | ALDH1A1 (0.50) | MAPTTHRBAURKACASP1TTK | |
| SCHEMBL8305924 | 0.79 | MAP4K4 (0.57) | MAPTTHRBNOTUMMCL1ALDH1A1 | |
| SCHEMBL10889799 | 0.79 | ESR1 (0.50) | MAPTALDH1A1MEN1KMT2AMAP4K4 | |
| SCHEMBL11161344 | 0.79 | ERCC1 (0.53) | MAPTNOTUMALDH1A1MAP4K4 | |
| SCHEMBL6674034 | 0.79 | MEN1 (0.47) | MAPTTHRBNOTUMALDH1A1KDM4E | |
| SCHEMBL11166857 | 0.79 | ALDH1A1 (0.67) | MAPTTHRBALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL1867386 | 0.79 | BCL2L1 (0.50) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL11537207 | 0.78 | KIF11 (0.39) | MAPTTHRBAURKACASP1TTK | |
| SCHEMBL611156 | 0.77 | PDE3B (0.52) | MAPTTHRBAURKACASP1TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036680-A | Anti-fibrotic pyridones | 英特穆恩公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| CN-117642399-A | Pyrrolopyridone derivatives useful for the treatment of cancer | 泰治疗有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| CN-110452216-B | Anti-fibrotic pyridinones | 英特穆恩公司 | 2022-08-26 | — | — | CN | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-4465686-A | 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones, their cardiotonic use and preparation | STERLING DRUG INC. (US) | 1984-08-14 | — | — | US | disclosed |
| EP-0109628-A1 | 2(1H)-pyridinones and preparation, useful as cardiotonics | STERLING DRUG INC. (US) | 1984-05-30 | — | — | EP | disclosed |
| US-4431651-A | 2-Pyridinones and their use as cardiotonic agents | STERLING DRUG INC. (US) | 1984-02-14 | — | — | US | disclosed |
| EP-0074091-A2 | 2(1H)-pyridinones and preparation thereof | STERLING DRUG INC. (US) | 1983-03-16 | — | — | EP | disclosed |
| EP-0017438-B1 | SUBSTITUTED 3-ALKYL-6-PHENYL-1,2,4-TRIAZOLO(4,3-A)PYRIDINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMERICAN CYANAMID COMPANY (US) | 1983-03-02 | — | — | EP | disclosed |
| EP-0061774-A2 | 3-Amino-5-(substituted)-2 (1H) pyridinones and 3-cyano compounds useful as cardiotonics and preparation thereof | STERLING DRUG INC. (US) | 1982-10-06 | — | — | EP | disclosed |
| US-4244953-A | Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines | AMERICAN CYANAMID COMPANY (US) | 1981-01-13 | — | — | US | disclosed |
| US-4242515-A | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines | AMERICAN CYANAMID COMPANY (US) | 1980-12-30 | — | — | US | disclosed |
| EP-0017438-A1 | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo(4,3-a)pyridines, processes for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1980-10-15 | — | — | EP | disclosed |
| US-4209626-A | Substituted 6-phenyl-1,2,4-triazolo[4,3-a]pyridines | AMERICAN CYANAMID COMPANY (US) | 1980-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MAPT 4222/4885THRB 4531/4885AURKA 2637/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MAPT 4222/4885THRB 4531/4885AURKA 2637/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | MAPT 4222/4885THRB 4531/4885AURKA 2637/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | MAPT 4222/4885THRB 4531/4885AURKA 2637/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | MAPT 3493/4885THRB 3121/4885AURKA 767/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | MAPT 3169/4885THRB 2050/4885AURKA 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.